HUE042373T2 - Aktív szenes szûrés benzodiazepin ADC-k tisztítására - Google Patents
Aktív szenes szûrés benzodiazepin ADC-k tisztításáraInfo
- Publication number
- HUE042373T2 HUE042373T2 HUE14763713A HUE14763713A HUE042373T2 HU E042373 T2 HUE042373 T2 HU E042373T2 HU E14763713 A HUE14763713 A HU E14763713A HU E14763713 A HUE14763713 A HU E14763713A HU E042373 T2 HUE042373 T2 HU E042373T2
- Authority
- HU
- Hungary
- Prior art keywords
- purification
- activated carbon
- carbon filtration
- benzodiazepine adcs
- benzodiazepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780131P | 2013-03-13 | 2013-03-13 | |
US201361782156P | 2013-03-14 | 2013-03-14 | |
US201361890067P | 2013-10-11 | 2013-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE042373T2 true HUE042373T2 (hu) | 2019-06-28 |
Family
ID=51537504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14763713A HUE042373T2 (hu) | 2013-03-13 | 2014-03-12 | Aktív szenes szûrés benzodiazepin ADC-k tisztítására |
Country Status (8)
Country | Link |
---|---|
US (1) | US9453046B2 (hu) |
EP (2) | EP3441072B1 (hu) |
CA (1) | CA2901312C (hu) |
DK (1) | DK2968494T3 (hu) |
ES (2) | ES2843786T3 (hu) |
HU (1) | HUE042373T2 (hu) |
PL (1) | PL2968494T3 (hu) |
WO (1) | WO2014143622A1 (hu) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9610361B2 (en) * | 2013-03-13 | 2017-04-04 | Seattle Genetics, Inc. | Cyclodextrin and antibody-drug conjugate formulations |
CN111164208B (zh) | 2017-09-29 | 2023-08-04 | 第一三共株式会社 | 抗体-吡咯并苯并二氮杂卓衍生物偶联物 |
CN117843795A (zh) * | 2019-03-11 | 2024-04-09 | 凯惠科技发展(上海)有限公司 | 一种含半胱氨酸的抗体、药物偶联物及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
EP1473301A3 (en) | 1997-06-04 | 2005-01-26 | Cornell Research Foundation, Inc. | Betulinol derivatives |
WO2003015871A2 (en) * | 2001-07-25 | 2003-02-27 | University Of North Carolina At Chapel Hill | Method and apparatus for rapid determination of ligand-protein binding using charcoal adsorption |
JP2009529522A (ja) * | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
PL2019104T3 (pl) | 2007-07-19 | 2014-03-31 | Sanofi Sa | Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
CA3014224C (en) | 2009-02-05 | 2022-05-24 | Immunogen, Inc. | Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
JP5875083B2 (ja) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
MX2012011900A (es) | 2010-04-15 | 2013-03-21 | Seattle Genetics Inc | Conjugados de pirrolobenzodiazepina diana. |
AR082319A1 (es) * | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
KR20190089048A (ko) | 2011-02-15 | 2019-07-29 | 이뮤노젠 아이엔씨 | 컨쥬게이트의 제조방법 |
US9096648B2 (en) | 2011-08-19 | 2015-08-04 | Emd Millipore Corporation | Methods of reducing level of one or more impurities in a sample during protein purification |
ES2687246T3 (es) | 2011-10-14 | 2018-10-24 | Seattle Genetics, Inc. | Pirrolobenzodiazepinas y conjugados dirigidos |
BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
EP3309162A1 (en) | 2011-10-14 | 2018-04-18 | Seattle Genetics, Inc. | Targeted conjugates of pyrrolobenzodiazepines |
-
2014
- 2014-03-12 EP EP18196228.3A patent/EP3441072B1/en active Active
- 2014-03-12 DK DK14763713.6T patent/DK2968494T3/en active
- 2014-03-12 HU HUE14763713A patent/HUE042373T2/hu unknown
- 2014-03-12 PL PL14763713T patent/PL2968494T3/pl unknown
- 2014-03-12 CA CA2901312A patent/CA2901312C/en active Active
- 2014-03-12 ES ES18196228T patent/ES2843786T3/es active Active
- 2014-03-12 US US14/774,348 patent/US9453046B2/en active Active
- 2014-03-12 WO PCT/US2014/024058 patent/WO2014143622A1/en active Application Filing
- 2014-03-12 ES ES14763713T patent/ES2702181T3/es active Active
- 2014-03-12 EP EP14763713.6A patent/EP2968494B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK2968494T3 (en) | 2019-03-04 |
WO2014143622A1 (en) | 2014-09-18 |
US20160039870A1 (en) | 2016-02-11 |
EP3441072B1 (en) | 2020-12-30 |
CA2901312A1 (en) | 2014-09-18 |
EP2968494B1 (en) | 2018-11-14 |
PL2968494T3 (pl) | 2019-04-30 |
US9453046B2 (en) | 2016-09-27 |
EP2968494A1 (en) | 2016-01-20 |
ES2843786T3 (es) | 2021-07-20 |
EP2968494A4 (en) | 2016-08-17 |
EP3441072A1 (en) | 2019-02-13 |
CA2901312C (en) | 2022-09-06 |
ES2702181T3 (es) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216429A1 (zh) | 用於純化芳基硫酸酯酶 的方法 | |
SG11201502555QA (en) | Purification system | |
EP2957306A4 (en) | BLOOD CLEANING COLUMN | |
ZA201506906B (en) | Regenerative recovery of contaminants from effluent gases | |
HK1209767A1 (en) | Purification of iduronate-2-sulfatase -2- | |
HUE056347T2 (hu) | Adszorbens összetétel argontisztításhoz | |
SG11201504635XA (en) | Gas purification filter unit | |
EP2964368A4 (en) | POINT-OF-USE FILTRATION SYSTEM COMPRISING A BACKLASH | |
ZA201603797B (en) | Novel purification processes | |
IL245155A0 (en) | Benzazepines are combined for the treatment of stuttering | |
HK1203202A1 (en) | Synthetic and purification methods for phosphaplatin compounds and uses thereof | |
ZA201604459B (en) | A wastewater purification system | |
EP2968494A4 (en) | ACTIVE CARBON FILTRATION FOR CLEANING BENZODIAZEPINE ADCS | |
HK1218959A1 (zh) | 雷帕霉素衍生物的純化 | |
IL243937A (en) | A process for the purification of compounds of diaminophenylazinium | |
GB201314581D0 (en) | Purification |